NCT05192798 2025-02-27
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Recruiting
Clinical Trials
11 trialsNCT05447702 2023-05-22
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital
Phase 2 Recruiting
NCT05556200 2023-04-12
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT03945604 2022-08-12
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT03075462 2022-07-01
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03243838 2022-02-02
LANCET
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT03932526 2019-04-30
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT03775928 2018-12-14
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT03348098 2017-11-28
Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT01176669 2015-09-09
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
Fudan University
Phase 2 Completed